Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ambrisentan - Gilead Sciences/GlaxoSmithKline

Drug Profile

Ambrisentan - Gilead Sciences/GlaxoSmithKline

Alternative Names: BSF 208075; GSK 1325760; GSK1325760A; Letairis; Volibris

Latest Information Update: 16 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott GmbH & Co. KG
  • Developer Gilead Sciences; GlaxoSmithKline
  • Class Antihypertensives; Phenylpropionates; Pyridazines; Small molecules
  • Mechanism of Action Endothelin A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pulmonary arterial hypertension; Pulmonary hypertension
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Pulmonary arterial hypertension
  • Phase III Pulmonary hypertension
  • Discontinued Idiopathic pulmonary fibrosis

Most Recent Events

  • 30 Sep 2019 GlaxoSmithKline initiates a phase I trial for Pulmonary arterial hypertension (In volunteers) in the United Kingdom (PO, Tablet) (NCT04095286)
  • 19 Sep 2019 GlaxoSmithKline plans a phase I trial in healthy volunteers (PO) (NCT04095286)
  • 08 Jul 2019 Ambrisentan is not yet available for Pulmonary arterial hypertension in Iceland and Liechtenstein
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top